Symbio is attending the AAD Annual Meeting
Meet Symbio at the AAD Annual Meeting in Denver, CO. Also attending? Schedule a time to meet with Symbio here.
Category: Featured
OCT Europe
Meet Symbio at OCT Europe
Symbio is attending OCT Europe in Barcelona, Spain. Also attending? Schedule a time to meet with Symbio here.
OCT East Coast
Connect with Symbio at OCT East Coast
Symbio is attending OCT Europe in Barcelona, Spain. Also attending? Schedule a time to meet with Symbio here.
EU Derm Drug Development Summit
Symbio is attending the EU Drug Development Summit
Meet Symbio at the EU Drug Development Summit in Amsterdam, Netherlands. Also attending? Schedule a time to meet with Symbio here.
Symbio Earns Their CIR Certificate
We’re proud to announce that we have earned our Crédit d’Impôt Recherche (CIR) certificate, signifying that the Ministry of Higher Education, Research and Innovation has approved us as a clinical research service provider in France.
The CIR certificate allows French sponsors to claim up to 30% of Symbio service fees as part of their eligible research and development (R&D) expenses tax credit — a clear financial advantage. It also demonstrates that:
- The French government recognizes and supports our scientific and R&D capabilities
- Our processes and documentation meet the requirements of French tax authorities
- French clients enjoy a reduced administrative burden during CIR reviews or audits
Contact our team today to learn more about what our CIR certificate means or to see what the proven CRO for dermatology, aesthetics, and inflammation can do for your trial.
Symbio Live Webinar: The Changing U.S. Healthcare Regulatory Landscape under President Trump
Symbio is excited to share details regarding our upcoming live webinar, “The Changing U.S. Healthcare Regulatory Landscape under President Trump”, presented by Patrick Ronan, Symbio Board Member and former FDA Chief of Staff.
Mr. Ronan will lead a discussion that explores the Trump Administration’s attempt to balance a healthcare agenda aimed at de-regulation and reducing the time and cost to develop medicines with other initiatives, such as most favored nation pricing, tariffs, tax and regulatory incentives to increase domestic manufacturing capabilities, expeditated review of therapies that align with national health priorities, and the reduction of staff and budget at key agencies such as the Food and Drug Administration (FDA) and the National Institutes of Health (NIH). More Details
Register
Can’t make the scheduled time? Register and we will send you the recording of the complete webinar.
Symbio, Clinical Research Organization (CRO), Announces Expansion with New Australia Office
New York, USA:
Symbio, a specialized therapeutic clinical research organization (CRO), is expanding it’s global presence with the opening of a new office and legal entity in Melbourne, Australia.
While Symbio has previously managed trials within Australia, the establishment of a dedicated local presence underscores the country’s growing strategic importance in global clinical research. The move reflects Symbio’s commitment to expanding its capabilities in the region and enhancing support for clients conducting trials in Australia. Access to exceptional investigators specializing in dermatology, combined with a strong regulatory environment and attractive government incentives for qualifying activities make Australia a key part of global development plans.
The new Melbourne office positions Symbio to further strengthen partnerships, streamline operations, and continue to contribute to the advancement of innovative therapies worldwide.
About Symbio:
With main offices in California, New York, Germany, France, and Australia, Symbio is a specialized global therapeutic clinical research organization with proven expertise in dermatology, aesthetics, inflammation, and gastroenterology across Phases I-IV, medical device, and non-interventional studies. Symbio offers full service CRO capabilities for both drug and device development. These services are further supported by a dedicated laboratory, manufacturing and packaging facility focused on topical formulation, research and development as well as small scale manufacturing, and clinical packaging and labelling services for all dosage forms.
EADV 2025 – Meet us in Paris!
Be sure to save the date and join Symbio at EADV Congress – Europe’s largest international meeting focused on dermatology and venereology, providing a platform for researchers, clinicians, and industry professionals to exchange knowledge, network, and present their latest research findings.
Paris, France
September 17 to 20, 2025
Symbio’s Shrutimita Pokhariyal Joins IDC2025 as Moderator and Speaker
Our colleague, Shrutimita Pokhariyal, will represent Symbio as both a Moderator and Speaker at the upcoming 6th International Conference on Dermatology and Cosmetology (IDC2025). Shrutimita will join an inspiring lineup of global experts dedicated to advancing skin science and clinical innovation. On June 2nd, from 3:40 PM to 4:00 PM CET, she will deliver a compelling presentation titled “Design of Experiment in Injectable Trials” and reflects her deep commitment to scientific excellence and thoughtful study design.
With her deep expertise in clinical development and commitment to scientific excellence, Shrutimita’s contribution underscores Symbio’s continued dedication to innovation, quality, and thought leadership in dermatological research. We look forward to her insights sparking meaningful dialogue and collaboration at IDC2025.
Symbio will be attending EAACI 2025 in Glasgow, United Kingdom, June 13-16.
Industry leaders will come together for this year’s premier event with an inspiring theme, “Breaking Boundaries in Allergy, Asthma, and Clinical Immunology: Integrating Planetary Health for a Sustainable Future”.
As a specialized Global CRO, Symbio is committed to advancing care in Allergy, Asthma and Immunology. With deep expertise in Dermatology, Inflammatory Disease, Aesthetics and Gastroenterology, we are excited to join global leaders advancing science and care in these critical areas.
Looking forward to connecting at EAACI and discussing how Symbio can accelerate progress with your clinical trials.